← Back to Search

Monoclonal Antibodies

Abatacept for Myasthenia Gravis

Phase < 1
Waitlist Available
Led By Daniel Drachman, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This pilot research study is being done to see if the drug abatacept (Orencia ®) will be helpful in treating patients with myasthenia gravis (MG) who do not respond satisfactorily to other drugs that are used to suppress the immune system. Abatacept has been successful in treating experimental MG in laboratory animals, and this study is to determine its effectiveness in patients with MG.

Eligible Conditions
  • Myasthenia Gravis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Muscle Strength (Dynamometry)
Objective Composite Score of Myasthenia Gravis (MG) Severity
Subjective Composite Score of Myasthenia Gravis (MG) Severity
Secondary study objectives
Acetylcholine Receptor (AChR) or Muscle-Specific Kinase (MuSK) Antibody Concentrations
Myasthenia Gravis Composite Score (MGC)
Myasthenia Gravis Quality of Life-15 (MG QOL15) Score

Side effects data

From 2016 Phase 4 trial • 3 Patients • NCT02078193
67%
COPD exacerbation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Belatacept

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: AbataceptExperimental Treatment1 Intervention
125mg abatacept in 1ml solution administered once per week by subcutaneous injection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abatacept
FDA approved

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbIndustry Sponsor
2,690 Previous Clinical Trials
4,097,534 Total Patients Enrolled
Johns Hopkins UniversityLead Sponsor
2,331 Previous Clinical Trials
14,874,451 Total Patients Enrolled
1 Trials studying Myasthenia Gravis
6 Patients Enrolled for Myasthenia Gravis
Daniel Drachman, MDPrincipal InvestigatorJohns Hopkins University
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top